Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

被引：23

作者：

Seo, Takuji ^{[1
]}

Noguchi, Emi ^{[1
]}

Yoshida, Masayuki ^{[2
]}

Mori, Taisuke ^{[2
]}

Tanioka, Maki ^{[1
]}

Sudo, Kazuki ^{[1
]}

Shimomura, Akihiko ^{[1
]}

Yonemori, Kan ^{[1
]}

Fujiwara, Yasuhiro ^{[1
]}

Tamura, Kenji ^{[1
]}

机构：

[1] Natl Canc Ctr, Dept Breast & Med Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan

[2] Natl Canc Ctr, Dept Pathol & Clin Labs, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan

来源：

CASE REPORTS IN ONCOLOGICAL MEDICINE | 2020年 / 2020卷

关键词：

SOLID TUMORS; CANCER; MELANOMA; AMPLIFICATION; INHIBITION; SURVIVAL; GENE; EGFR;

D O I：

10.1155/2020/2518383

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. Metaplastic breast carcinomas are rare and carry poor prognoses. They are also more aggressive than other breast cancers and are known for their resistance to chemotherapy. Prolonged treatment with dabrafenib and trametinib is a therapy for malignant melanoma that improves the progression-free survival and overall survival. Such molecular-targeted therapies are also being developed for cancers with BRAF mutation, a driver of malignant melanoma. Case Presentation. A 57-year-old woman with metaplastic breast cancer and chemotherapy-refractory massive pleural effusion. After contained anthracycline regimen failure, her breast cancer progressed to an advanced stage. We ordered next-generation sequencing- (NGS-) based tumor molecular profiling from core needle biopsy of the breast. The NGS report indicated the presence of a BRAF V600E mutation. After initiation of dabrafenib and trametinib, her symptom and the pleural effusion were decreased. The first assessment of CT scans showed a decreased pleural effusion and shrunken subcutaneous lesions. Approximately 2 weeks later, a new lesion appeared. She died from 12 weeks after initiation of dabrafenib and trametinib treatment. Conclusion. To the best of our knowledge, this is the first report of BRAF mutation breast cancer treated with dabrafenib and trametinib and it heralds the possibility of targeted therapy for rare breast cancers.

引用

页数：6

共 25 条

[1] BRAF genomic alterations in breast cancer [J].

Albanell, J. ;

Elvin, J. A. ;

Suh, J. ;

Vergilio, J-A. ;

Le, I. Phuong ;

Kaklamani, V. ;

Ali, S. ;

Miller, V. ;

Stephens, P. ;

Gay, L. M. ;

Ross, J. S. .

ANNALS OF ONCOLOGY, 2016, 27

[2] BRAF: An emerging target for triple-negative breast cancer [J].

Albanell, Joan ;

Elvin, Julia Andrea ;

Ali, Siraj Mahamed ;

Schrock, Alexa Betzig ;

Chung, Jon ;

Vergilio, Jo-Anne ;

Suh, James ;

Ramkissoon, Shakti ;

Severson, Eric Allan ;

Daniel, Sugganth ;

Miller, Vincent A. ;

Stephens, Philip J. ;

Gay, Laurie M. ;

Ross, Jeffrey S. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[3] Mutations of the BRAF gene in human cancer [J].

Davies, H ;

Bignell, GR ;

Cox, C ;

Stephens, P ;

Edkins, S ;

Clegg, S ;

Teague, J ;

Woffendin, H ;

Garnett, MJ ;

Bottomley, W ;

Davis, N ;

Dicks, N ;

Ewing, R ;

Floyd, Y ;

Gray, K ;

Hall, S ;

Hawes, R ;

Hughes, J ;

Kosmidou, V ;

Menzies, A ;

Mould, C ;

Parker, A ;

Stevens, C ;

Watt, S ;

Hooper, S ;

Wilson, R ;

Jayatilake, H ;

Gusterson, BA ;

Cooper, C ;

Shipley, J ;

Hargrave, D ;

Pritchard-Jones, K ;

Maitland, N ;

Chenevix-Trench, G ;

Riggins, GJ ;

Bigner, DD ;

Palmieri, G ;

Cossu, A ;

Flanagan, A ;

Nicholson, A ;

Ho, JWC ;

Leung, SY ;

Yuen, ST ;

Weber, BL ;

Siegler, HF ;

Darrow, TL ;

Paterson, H ;

Marais, R ;

Marshall, CJ ;

Wooster, R .

NATURE, 2002, 417 (6892) :949-954

[4] Whole exome sequencing of rare aggressive breast cancer histologies [J].

Dieci, Maria Vittoria ;

Smutna, Veronika ;

Scott, Veronique ;

Yin, Guangliang ;

Xu, Ran ;

Vielh, Philippe ;

Mathieu, Marie-Christine ;

Vicier, Cecile ;

Laporte, Melanie ;

Drusch, Francoise ;

Guarneri, Valentina ;

Conte, Pierfranco ;

Delaloge, Suzette ;

Lacroix, Ludovic ;

Fromigue, Olivia ;

Andre, Fabrice ;

Lefebvre, Celine .

BREAST CANCER RESEARCH AND TREATMENT, 2016, 156 (01) :21-32

[5] Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial [J].

Falchook, Gerald S. ;

Long, Georgina V. ;

Kurzrock, Razelle ;

Kim, Kevin B. ;

Arkenau, Tobias H. ;

Brown, Michael P. ;

Hamid, Omid ;

Infante, Jeffrey R. ;

Millward, Michael ;

Pavlick, Anna C. ;

O'Day, Steven J. ;

Blackman, Samuel C. ;

Curtis, C. Martin ;

Lebowitz, Peter ;

Ma, Bo ;

Ouellet, Daniele ;

Kefford, Richard F. .

LANCET, 2012, 379 (9829) :1893-1901

[6] Comprehensive molecular portraits of human breast tumours [J].

Koboldt, Daniel C. ;

Fulton, Robert S. ;

McLellan, Michael D. ;

Schmidt, Heather ;

Kalicki-Veizer, Joelle ;

McMichael, Joshua F. ;

Fulton, Lucinda L. ;

Dooling, David J. ;

Ding, Li ;

Mardis, Elaine R. ;

Wilson, Richard K. ;

Ally, Adrian ;

Balasundaram, Miruna ;

Butterfield, Yaron S. N. ;

Carlsen, Rebecca ;

Carter, Candace ;

Chu, Andy ;

Chuah, Eric ;

Chun, Hye-Jung E. ;

Coope, Robin J. N. ;

Dhalla, Noreen ;

Guin, Ranabir ;

Hirst, Carrie ;

Hirst, Martin ;

Holt, Robert A. ;

Lee, Darlene ;

Li, Haiyan I. ;

Mayo, Michael ;

Moore, Richard A. ;

Mungall, Andrew J. ;

Pleasance, Erin ;

Robertson, A. Gordon ;

Schein, Jacqueline E. ;

Shafiei, Arash ;

Sipahimalani, Payal ;

Slobodan, Jared R. ;

Stoll, Dominik ;

Tam, Angela ;

Thiessen, Nina ;

Varhol, Richard J. ;

Wye, Natasja ;

Zeng, Thomas ;

Zhao, Yongjun ;

Birol, Inanc ;

Jones, Steven J. M. ;

Marra, Marco A. ;

Cherniack, Andrew D. ;

Saksena, Gordon ;

Onofrio, Robert C. ;

Pho, Nam H. .

NATURE, 2012, 490 (7418) :61-70

[7]

Lakhani S.R., WHO Classification of Tumours of the Breast, VFourth

[8] Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma [J].

Long, G. V. ;

Stroyakovskiy, D. ;

Gogas, H. ;

Levchenko, E. ;

de Braud, F. ;

Larkin, J. ;

Garbe, C. ;

Jouary, T. ;

Hauschild, A. ;

Grob, J. J. ;

Sileni, V. Chiarion ;

Lebbe, C. ;

Mandala, M. ;

Millward, M. ;

Arance, A. ;

Bondarenko, I. ;

Haanen, J. B. A. G. ;

Hansson, J. ;

Utikal, J. ;

Ferraresi, V. ;

Kovalenko, N. ;

Mohr, P. ;

Probachai, V. ;

Schadendorf, D. ;

Nathan, P. ;

Robert, C. ;

Ribas, A. ;

DeMarini, D. J. ;

Irani, J. G. ;

Casey, M. ;

Ouellet, D. ;

Martin, A. -M. ;

Le, N. ;

Patel, K. ;

Flaherty, K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (20) :1877-1888

[9] Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial [J].

Long, Georgina V. ;

Stroyakovskiy, Daniil ;

Gogas, Helen ;

Levchenko, Evgeny ;

de Braud, Filippo ;

Larkin, James ;

Garbe, Claus ;

Jouary, Thomas ;

Hauschild, Axel ;

Grob, Jean-Jacques ;

Chiarion-Sileni, Vanna ;

Lebbe, Celeste ;

Mandala, Mario ;

Millward, Michael ;

Arance, Ana ;

Bondarenko, Igor ;

Haanen, John B. A. G. ;

Hansson, Johan ;

Utikal, Jochen ;

Ferraresi, Virginia ;

Kovalenko, Nadezhda ;

Mohr, Peter ;

Probachai, Volodymr ;

Schadendorf, Dirk ;

Nathan, Paul ;

Robert, Caroline ;

Ribas, Antoni ;

DeMarini, Douglas J. ;

Irani, Jhangir G. ;

Swann, Suzanne ;

Legos, Jeffrey J. ;

Jin, Fan ;

Mookerjee, Bijoyesh ;

Flaherty, Keith .

LANCET, 2015, 386 (9992) :444-451

[10] Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma [J].

Long, Georgina V. ;

Fung, Carina ;

Menzies, Alexander M. ;

Pupo, Gulietta M. ;

Carlino, Matteo S. ;

Hyman, Jessica ;

Shahheydari, Hamideh ;

Tembe, Varsha ;

Thompson, John F. ;

Saw, Robyn P. ;

Howle, Julie ;

Hayward, Nicholas K. ;

Johansson, Peter ;

Scolyer, Richard A. ;

Kefford, Richard F. ;

Rizos, Helen .

NATURE COMMUNICATIONS, 2014, 5

← 1 2 3 →